Print Share

New treatment options for advanced-stage cancer patients revealed through next-generation sequencing test

Institution:

Weill Cornell Medicine

Researchers:

Olivier Elemento, PhD, associate professor of computational genomics in computational biomedicine and of physiology and biophysics at Weill Cornell Medicine

Impact:

Researchers have developed a powerful new test that scans thousands of genes to reveal untapped therapies for patients with advanced cancers. The test, EXaCT-1, identifies alterations within tumors — some of which drive cancerous growth — on a magnitude up to hundreds of times greater than similar technologies designed to pinpoint the most precise ways of treating the disease.

Timeline:

2015

Topics

AgingBasic ScienceCancerCardiovascularClinical ResearchDiagnosticsDrug DevelopmentFeaturedGeneticsImmune SystemInfectious DiseaseMedical DeviceMental HealthNeurodegenerativeNobel PrizePediatricsPublic HealthRespiratorySurgical AdvancementTechnologyTreatment AdvancesVaccines

Schools

Albany Medical CollegeAlbert Einstein College of MedicineCity University of New York School of MedicineColumbia University College Of Physicians and SurgeonsHofstra Northwell School of Medicine at Hofstra UniversityIcahn School of Medicine at Mount SinaiJacobs School of Medicine and Biomedical Sciences, the University at BuffaloNew York Institute of Technology College of Osteopathic MedicineNew York Medical CollegeNew York University School of MedicineSchool of Medicine and Dentistry at the University of Rochester Medical CenterStony Brook University School of MedicineSUNY Downstate Medical CenterSUNY Upstate Medical UniversityTouro College of Osteopathic MedicineWeill Cornell MedicineWeill Cornell Medicine, NewYork-Presbyterian